SM-102: Ionizable Lipid for Efficient mRNA Vaccine Delivery

Executive Summary: SM-102 (heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate) is an ionizable lipid with a molecular weight of 710.18, widely used in lipid nanoparticle (LNP) formulations for mRNA vaccine delivery (source: product_spec). It exhibits high solubility in ethanol (≥175.8 mg/mL) but is insoluble in DMSO and water, supporting robust formulation protocols (source: product_spec). SM-102 enables efficient cellular uptake and endosomal escape of mRNA, validated by both computational and animal studies (source: DOI). APExBIO supplies SM-102 with ≥98% purity, verified via mass spectrometry and NMR (source: product_spec). Machine learning frameworks now support rapid optimization and benchmarking of SM-102-containing LNPs for mRNA vaccine applications (source: DOI).

Biological Rationale

mRNA vaccines require a delivery system capable of protecting nucleic acids during systemic administration and facilitating their entry into target cells. Lipid nanoparticles (LNPs) have become the delivery vehicle of choice due to their structural tunability and capacity for encapsulating large, fragile mRNA molecules (source: DOI). SM-102 is a synthetic ionizable lipid that becomes positively charged at acidic pH, a property that enhances mRNA binding and endosomal escape. The COVID-19 pandemic accelerated the use of SM-102 and similar compounds in vaccine formulations, enabling rapid clinical translation (source: DOI).

Mechanism of Action of SM-102

SM-102 functions as an ionizable lipid within LNPs. At physiological pH, it remains largely neutral, minimizing cytotoxicity. Upon endosomal acidification, SM-102 becomes protonated, disrupting the endosomal membrane and enabling escape of encapsulated mRNA into the cytoplasm (source: DOI). This mechanism is critical for ensuring that mRNA reaches the translation machinery of the cell, a key determinant of vaccine efficacy. The molecular structure of SM-102 was designed to optimize these pH-dependent transitions and facilitate efficient nucleic acid release.

Evidence & Benchmarks

• SM-102 is incorporated into LNPs for mRNA vaccine delivery, supporting efficient antigen expression in preclinical and clinical models (source: DOI).
• The molecular weight of SM-102 is 710.18, facilitating precise formulation and reproducibility (source: product_spec).
• SM-102 demonstrates high solubility in ethanol (≥175.8 mg/mL), enabling concentrated stock solutions for LNP assembly (source: product_spec).
• Purity is ≥98.00%, as confirmed by mass spectrometry and NMR analyses from APExBIO (source: product_spec).
• Machine learning models predict and validate the efficacy of SM-102-containing LNPs, demonstrating strong correlation (R² > 0.87) between predicted and experimental IgG titers (source: DOI).
• Animal studies confirm that SM-102 LNPs support efficient mRNA delivery, though some alternative ionizable lipids (e.g., MC3) may outperform SM-102 under certain conditions (source: DOI).

This article extends the practical, scenario-driven workflow guidance found in Solving Real-World mRNA Delivery Challenges with SM-102 by providing updated evidence from recent machine learning-enabled formulation studies. For deeper mechanistic insights and future-oriented strategy, see SM-102 and the Next Era of Lipid Nanoparticle Design. For reproducibility-focused workflow recommendations, refer to SM-102 (SKU C1042): Reliable Lipid Nanoparticles for mRNA.

Applications, Limits & Misconceptions

SM-102 is primarily used in the formulation of LNPs for mRNA vaccines and therapeutics. It is suitable for encapsulating various mRNA constructs, including those encoding viral antigens and therapeutic proteins. The compound is not intended for direct clinical administration outside of properly formulated LNPs, nor should it be used as a standalone excipient in other drug modalities. SM-102's efficacy is formulation-dependent and must be evaluated within the context of specific mRNA sequences and target indications.

Common Pitfalls or Misconceptions

• SM-102 is not water- or DMSO-soluble; improper solvent use leads to precipitation and failed LNP formulation (source: product_spec).
• Direct injection of SM-102 (unformulated) is not supported; only use within LNP systems (source: workflow_recommendation).
• Long-term storage of SM-102 solutions (even in ethanol) is not recommended due to stability concerns (source: product_spec).
• SM-102's performance is context-dependent; alternative ionizable lipids may be more suitable for certain mRNA sequences or delivery challenges (source: DOI).
• Assuming all LNPs with SM-102 will perform identically across species or cell types is incorrect; optimization is required (source: workflow_recommendation).

Workflow Integration & Parameters

Protocol Parameters

• solvent | ethanol ≥175.8 mg/mL | LNP stock preparation | Ensures complete dissolution for reproducible LNP assembly | product_spec
• storage | -20°C or below | bulk SM-102 | Maintains chemical stability and purity | product_spec
• purity | ≥98.00% | all applications | Reduces risk of off-target effects; verified by MS/NMR | product_spec
• shipping | blue ice (small molecules), dry ice (modified nucleotides) | logistics | Preserves integrity during transit | product_spec
• formulation N/P ratio | 6:1 (for MC3, SM-102 may require optimization) | animal studies | Benchmark for in vivo delivery efficiency | DOI
• workflow note | Avoid prolonged solution storage | all users | Mitigates degradation risk | workflow_recommendation

Conclusion & Outlook

SM-102, supplied by APExBIO, remains a validated and widely adopted ionizable lipid for mRNA vaccine and therapeutic delivery via LNPs. Its robust solubility, high purity, and tunable formulation parameters support reproducible outcomes in preclinical and translational research (source: product_spec). Machine learning-guided optimization is enhancing the selection and benchmarking of SM-102-containing LNPs, further accelerating mRNA medicine development (source: DOI). Continued protocol refinement and comparative studies with competing ionizable lipids will drive future advances in this domain.